by user | Jan 27, 2016 | Clinical Trials
San Diego, California, January 27, 2016: Stemedica Cell Technologies, Inc. announced completion of enrollment into “A Phase I/IIa, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic...
by user | Oct 13, 2015 | Publications
Abstract Aims: This article describes an ongoing study investigating the safety and efficacy of ischemia-tolerant mesenchymal stem cell (MSC) therapy in patients with nonischemic heart failure and dysfunctional viable myocardium without scarring. This study will...
by user | Sep 1, 2015 | Publications
Possible Modulating Effects of Paracrine Activities of Stem Cells Abstract Over the past 1.5 decades, numerous stem cell trials have been performed in patients with cardiovascular disease. Although encouraging outcome signals have been reported, these have been small,...
by user | Apr 22, 2014 | Company Initiatives
Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes Byung-Geon “BG” Rhee, Ph.D., President of Green Cross Holdings, a South Korean biopharmaceutical company, to its board of directors. Green Cross,...
by user | Feb 12, 2014 | Company Initiatives
Stemedica announced today that Richard Mejia, Jr. has joined the Company’s Board of Directors and will be Chairman of the Company’s Audit Committee effective January 31, 2014. Mr. Mejia spent 38 years with Ernst & Young, LLP where he was a partner for 25 years. He...
